Urinary melatonin levels, sleep disruption, and risk of prostate cancer in elderly men
- PMID: 25107635
- PMCID: PMC4318783
- DOI: 10.1016/j.eururo.2014.07.008
Urinary melatonin levels, sleep disruption, and risk of prostate cancer in elderly men
Abstract
Melatonin has anticarcinogenic properties in experimental models. We undertook a case-cohort study of 928 Icelandic men without prostate cancer (PCa) nested within the Age, Gene/Environment Susceptibility (AGES)-Reykjavik cohort to investigate the prospective association between first morning-void urinary 6-sulfatoxymelatonin (aMT6s) levels and the subsequent risk for PCa, under the hypothesis that men with lower aMT6s levels have an increased risk for advanced PCa. We used weighted Cox proportional hazards models to assess the association between first morning-void aMT6s levels and PCa risk, adjusting for potential confounders. A total of 111 men were diagnosed with incident PCa, including 24 with advanced disease. Men who reported sleep problems at baseline had lower morning aMT6s levels compared with those who reported no sleep problems. Men with morning aMT6s levels below the median had a fourfold statistically significant increased risk for advanced disease compared with men with levels above the median (hazard ratio: 4.04; 95% confidence interval, 1.26-12.98). These results require replication in larger prospective studies with longer follow-up.
Patient summary: In this report, we evaluated the prospective association between urinary aMT6s levels and risk of PCa in an Icelandic population. We found that lower levels of aMT6s were associated with an increased risk for advanced PCa.
Keywords: Circadian rhythm; Melatonin levels; Prostate cancer.
Copyright © 2014 European Association of Urology. All rights reserved.
Figures

Comment in
-
Melatonin, sleep, and prostate cancer in elderly men: study, hypothesis development, and icelandic options.Eur Urol. 2015 Feb;67(2):195-7. doi: 10.1016/j.eururo.2014.09.033. Epub 2014 Oct 1. Eur Urol. 2015. PMID: 25282366 No abstract available.
References
-
- Blask DE, Dauchy RT, Sauer LA. Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal. Endocrine. 2005;27:179–88. - PubMed
-
- Moretti RM, Marelli MM, Maggi R, Dondi D, Motta M, Limonta P. Antiproliferative action of melatonin on human prostate cancer LNCaP cells. Oncol Rep. 2000;7:347–51. - PubMed
-
- Bartsch C, Bartsch H, Schmidt A, Ilg S, Bichler KH, Flüchter SH. Melatonin and 6-sulfatoxymelatonin circadian rhythms in serum and urine of primary prostate cancer patients: evidence for reduced pineal activity and relevance of urinary determinations. Clin Chim Acta. 1992;209:153–67. - PubMed
-
- Bojkowski CJ, Aldhous ME, English J, et al. Suppression of nocturnal plasma melatonin and 6-sulphatoxymelatonin by bright and dim light in man. Horm Metab Res. 1987;19:437–40. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- N01 AG012100/AG/NIA NIH HHS/United States
- T32-CA-09001-35/CA/NCI NIH HHS/United States
- R25 CA098566/CA/NCI NIH HHS/United States
- R25-CA-098566/CA/NCI NIH HHS/United States
- UL1 RR025758/RR/NCRR NIH HHS/United States
- KL2 RR025757/RR/NCRR NIH HHS/United States
- P01-AG-009975/AG/NIA NIH HHS/United States
- KL2 TR001100/TR/NCATS NIH HHS/United States
- KL2-RR-025757/RR/NCRR NIH HHS/United States
- P01 AG009975/AG/NIA NIH HHS/United States
- UL1-RR-025758/RR/NCRR NIH HHS/United States
- T32 CA009001/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical